Evidence map›Paper›PMID 39512510›Full record

ArticleOncology letters2025

Treatment of lung adenocarcinoma with chemotherapy helps mitigate chronic myeloid leukaemia progression: A case report.

Kazunori Nagasue, Ryotaro Kida, Ryota Shigaki, Kiichi Nitanai, Akari Yagita, Hiraku Yanada, Yasuhiro Umekage, Chie Mori, Yoshinori Minami, Takuya Funayama and 4 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kazunori NagasueDepartment of Internal Medicine, Division of Respiratory Medicine and Neurology, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan.
Ryotaro KidaDepartment of Internal Medicine, Division of Respiratory Medicine and Neurology, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan.
Ryota ShigakiDepartment of Internal Medicine, Division of Respiratory Medicine and Neurology, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan.
Kiichi NitanaiDepartment of Internal Medicine, Division of Respiratory Medicine and Neurology, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan.
Akari YagitaDepartment of Internal Medicine, Division of Respiratory Medicine and Neurology, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan.
Hiraku YanadaDepartment of Internal Medicine, Division of Respiratory Medicine and Neurology, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan.
Yasuhiro UmekageDepartment of Internal Medicine, Division of Respiratory Medicine and Neurology, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan.
Chie MoriDepartment of Internal Medicine, Division of Respiratory Medicine and Neurology, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan.
Yoshinori MinamiDepartment of Internal Medicine, Division of Respiratory Medicine and Neurology, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan.
Takuya FunayamaDepartment of Internal Medicine, Division of Hematology, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan.
Masayo YamamotoDepartment of Internal Medicine, Division of Hematology, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan.
Mishie TaninoDepartment of Diagnostic Pathology, Asahikawa Medical University Hospital, Asahikawa, Hokkaido 078-8510, Japan.
Ryohei YoshidaDepartment of Internal Medicine, Division of Respiratory Medicine and Neurology, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan.
Takaaki SasakiDepartment of Internal Medicine, Division of Respiratory Medicine and Neurology, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment outcomes for inoperable advanced non-small cell lung cancer have improved in recent years. However, information on coexisting haematological tumours is lacking. The present patient was a 65-year-old woman with stage IVA lung adenocarcinoma. The patient was administered a combination of platinum therapy and immune checkpoint inhibitors. The patient was subsequently diagnosed with chronic myeloid leukaemia (CML) following leukocytosis. Carboplatin and pemetrexed combination therapy resulted in shrinkage of lung cancer. Improvements in peripheral blood leukocyte counts and bone marrow findings were observed. These results suggested that the treatment of lung cancer may control the course of CML.

Indexed as

CMLNSCLCt-MN

Identifiers

PMID39512510
PMCPMC11542147

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.